Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
430.14
+4.13 (0.97%)
At close: Apr 28, 2026, 4:00 PM EDT
428.13
-2.01 (-0.47%)
After-hours: Apr 28, 2026, 7:57 PM EDT
Vertex Pharmaceuticals Employees
Vertex Pharmaceuticals had 6,400 employees as of December 31, 2025. The number of employees increased by 300 or 4.92% compared to the previous year.
Employees
6,400
Change (1Y)
300
Growth (1Y)
4.92%
Revenue / Employee
$1,875,203
Profits / Employee
$617,688
Market Cap
109.41B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6,400 | 300 | 4.92% |
| Dec 31, 2024 | 6,100 | 700 | 12.96% |
| Dec 31, 2023 | 5,400 | 600 | 12.50% |
| Dec 31, 2022 | 4,800 | 900 | 23.08% |
| Dec 31, 2021 | 3,900 | 500 | 14.71% |
| Dec 31, 2020 | 3,400 | 400 | 13.33% |
| Dec 31, 2019 | 3,000 | 500 | 20.00% |
| Dec 31, 2018 | 2,500 | 200 | 8.70% |
| Dec 31, 2017 | 2,300 | 150 | 6.98% |
| Dec 31, 2016 | 2,150 | 200 | 10.26% |
| Dec 31, 2015 | 1,950 | 120 | 6.56% |
| Dec 31, 2014 | 1,830 | 30 | 1.67% |
| Dec 31, 2013 | 1,800 | -400 | -18.18% |
| Dec 31, 2012 | 2,200 | 200 | 10.00% |
| Dec 31, 2011 | 2,000 | 309 | 18.27% |
| Dec 31, 2010 | 1,691 | 259 | 18.09% |
| Dec 31, 2009 | 1,432 | 99 | 7.43% |
| Dec 31, 2008 | 1,333 | 183 | 15.91% |
| Dec 31, 2007 | 1,150 | 188 | 19.54% |
| Dec 31, 2006 | 962 | 149 | 18.33% |
| Dec 31, 2005 | 813 | 77 | 10.46% |
| Dec 31, 2004 | 736 | 12 | 1.66% |
| Dec 31, 2003 | 724 | -256 | -26.12% |
| Dec 31, 2002 | 980 | -20 | -2.00% |
| Dec 31, 2001 | 1,000 | 545 | 119.78% |
| Dec 31, 2000 | 455 | 102 | 28.90% |
| Dec 31, 1999 | 353 | 13 | 3.82% |
| Dec 31, 1998 | 340 | 120 | 54.55% |
| Dec 31, 1997 | 220 | 42 | 23.60% |
| Dec 31, 1996 | 178 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Regeneron Pharmaceuticals | 15,410 |
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| argenx SE | 1,863 |
| Insmed | 1,664 |
VRTX News
- 22 days ago - Vertex to Announce First Quarter 2026 Financial Results on May 4th - Business Wire
- 27 days ago - Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States - Business Wire
- 5 weeks ago - TrumpRx lists many medicines at prices higher than paid in UK - Reuters
- 6 weeks ago - Vertex Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts
- 7 weeks ago - This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results - Investopedia
- 7 weeks ago - Vertex passes key test In quest to treat kidney diseases - CNBC
- 7 weeks ago - Vertex Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Vertex's kidney disease drug meets main goal in late-stage trial - Reuters